Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa M Ott

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Frontiers in Immunology|June 9, 2015
Novel Genome-Editing Tools to Model and Correct Primary ImmunodeficienciesLisa M Ott de Bruin, Stefano Volpi, Kiran Musunuru
Depression and Anxiety|October 25, 2007
Stuck in the past: negative bias, explanatory style, temporal order, and evaluative perspectives in life narratives of clinically depressed individualsTilmann Habermas, Lisa-M Ott, Merve Schubert, et al.
Current Opinion in Allergy and Clinical Immunology|October 17, 2023
Advances in gene therapy for inborn errors of immunityLisa M Ott de Bruin, Arjan C Lankester, Frank J T Staal
Behavior Modification|December 13, 2012
Detecting false positives in A-B designs: potential implications for practitionersTyler K Krueger, John T Rapp, Lisa M Ott, et al.
Immunology Letters|September 20, 2024
Gene therapy strategies for RAG1 deficiency: Challenges and breakthroughsGiorgio Gilioli, Arjan C Lankester, Sander de Kivit, et al.
International Journal of Molecular Sciences|November 14, 2023
Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell DefectLisa M Ott de Bruin, Ingrid Pico-Knijnenburg, Monique M van Ostaijen-Ten Dam, et al.
Blood Advances|August 19, 2025
RAG1 lentiviral gene therapy restores T cell development of RAG1-SCID patient cells in artificial thymic organoidsXiaolin Meng, Janine E Melsen, Rosalie van der Holst, et al.
Frontiers in Immunology|November 29, 2023
Partial correction of immunodeficiency by lentiviral vector gene therapy in mouse models carrying <i>Rag1</i> hypomorphic mutationsMaria Carmina Castiello, Martina Di Verniere, Elena Draghici, et al.
The Journal of Allergy and Clinical Immunology|May 5, 2019
Cysteine and hydrophobic residues in CDR3 serve as distinct T-cell self-reactivity indicesStephen R Daley, Hui-Fern Koay, Kerry Dobbs, et al.
Frontiers in Immunology|October 19, 2017
Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56<sup>bright</sup> NKG2A<sup>+++</sup> Cells, and Yet Display Increased Degranulation and Higher Perforin ContentKerry Dobbs, Giovanna Tabellini, Enrica Calzoni, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Frontiers in Immunology|June 9, 2015
Novel Genome-Editing Tools to Model and Correct Primary ImmunodeficienciesLisa M Ott de Bruin, Stefano Volpi, Kiran Musunuru
Depression and Anxiety|October 25, 2007
Stuck in the past: negative bias, explanatory style, temporal order, and evaluative perspectives in life narratives of clinically depressed individualsTilmann Habermas, Lisa-M Ott, Merve Schubert, et al.
Current Opinion in Allergy and Clinical Immunology|October 17, 2023
Advances in gene therapy for inborn errors of immunityLisa M Ott de Bruin, Arjan C Lankester, Frank J T Staal
Behavior Modification|December 13, 2012
Detecting false positives in A-B designs: potential implications for practitionersTyler K Krueger, John T Rapp, Lisa M Ott, et al.
Immunology Letters|September 20, 2024
Gene therapy strategies for RAG1 deficiency: Challenges and breakthroughsGiorgio Gilioli, Arjan C Lankester, Sander de Kivit, et al.
International Journal of Molecular Sciences|November 14, 2023
Persistent Hypogammaglobulinemia after Receiving Rituximab Post-HSCT Is Not Caused by an Intrinsic B Cell DefectLisa M Ott de Bruin, Ingrid Pico-Knijnenburg, Monique M van Ostaijen-Ten Dam, et al.
Blood Advances|August 19, 2025
RAG1 lentiviral gene therapy restores T cell development of RAG1-SCID patient cells in artificial thymic organoidsXiaolin Meng, Janine E Melsen, Rosalie van der Holst, et al.
Frontiers in Immunology|November 29, 2023
Partial correction of immunodeficiency by lentiviral vector gene therapy in mouse models carrying <i>Rag1</i> hypomorphic mutationsMaria Carmina Castiello, Martina Di Verniere, Elena Draghici, et al.
The Journal of Allergy and Clinical Immunology|May 5, 2019
Cysteine and hydrophobic residues in CDR3 serve as distinct T-cell self-reactivity indicesStephen R Daley, Hui-Fern Koay, Kerry Dobbs, et al.
Frontiers in Immunology|October 19, 2017
Corrigendum: Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56<sup>bright</sup> NKG2A<sup>+++</sup> Cells, and Yet Display Increased Degranulation and Higher Perforin ContentKerry Dobbs, Giovanna Tabellini, Enrica Calzoni, et al.
Pageof 2